{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:30:26Z","timestamp":1789072226347,"version":"build-2803163510"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA178999"],"award-info":[{"award-number":["R01CA178999"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA178999S1"],"award-info":[{"award-number":["R01CA178999S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA254403"],"award-info":[{"award-number":["R01CA254403"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA254403-04S1"],"award-info":[{"award-number":["R01CA254403-04S1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA254403-04S2"],"award-info":[{"award-number":["R01CA254403-04S2"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U54CA274513"],"award-info":[{"award-number":["U54CA274513"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["CA160771"],"award-info":[{"award-number":["CA160771"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA254403"],"award-info":[{"award-number":["R01CA254403"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K01CA226346"],"award-info":[{"award-number":["K01CA226346"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["R01AI162633"],"award-info":[{"award-number":["R01AI162633"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["R01AI136581"],"award-info":[{"award-number":["R01AI136581"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Diffuse large B-cell lymphoma (DLBCL) is a commonly diagnosed, aggressive non-Hodgkin's lymphoma. While R-CHOP chemoimmunotherapy is potentially curative, about 40% of DLBCL patients will fail, highlighting the need to identify biomarkers to optimize management. SAMHD1 has a dNTPase-independent role in promoting resection to facilitate DNA double-strand break (DSB) repair by homologous recombination. We evaluated the relationship of SAMHD1 levels with sensitivity to DSB-sensitizing agents in DLBCL cells and the association of SAMHD1 expression with clinical outcomes in 79 DLBCL patients treated with definitive therapy and an independent cohort dataset of 234 DLBCL patients. Low SAMHD1 expression, Vpx-mediated, or siRNA-mediated degradation\/depletion in DLBCL cells was associated with greater sensitivity to doxorubicin and PARP inhibitors. On Kaplan\u2013Meier log-rank survival analysis, low SAMHD1 expression was associated with improved overall survival (OS), which on subset analysis remained significant only in patients with advanced stage (III-IV) and moderate to high risk (2\u20135 International Prognostic Index (IPI)). The association of low SAMHD1 expression with improved OS remained significant on multivariate analysis independent of other adverse factors, including IPI, and was validated in an independent cohort. Our findings suggest that SAMHD1 expression mediates doxorubicin resistance and may be an important prognostic biomarker in advanced, higher-risk DLBCL patients.<\/jats:p>","DOI":"10.1093\/narcan\/zcae007","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T21:21:50Z","timestamp":1708809710000},"source":"Crossref","is-referenced-by-count":5,"title":["SAMHD1 expression contributes to doxorubicin resistance and predicts survival outcomes in diffuse large B-cell lymphoma patients"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1197-0742","authenticated-orcid":false,"given":"Waaqo","family":"Daddacha","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University , Augusta , GA\u00a0 30912 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5714-2518","authenticated-orcid":false,"given":"Dominique","family":"Monroe","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University , Augusta , GA\u00a0 30912 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley\u00a0J","family":"Schlafstein","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison\u00a0E","family":"Withers","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth\u00a0B","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Danelia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nho\u00a0C","family":"Luong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatmata","family":"Sesay","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip\u00a0K","family":"Rath","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edidiong\u00a0R","family":"Usoro","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University , Augusta , GA\u00a0 30912 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00a0E","family":"Essien","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew\u00a0T","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmeng\u00a0G","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan","family":"Mahboubi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine , Atlanta , GA\u00a0 30322 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arilyn","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University , Augusta , GA\u00a0 30912 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia\u00a0E","family":"Steinbeck","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University , Augusta , GA\u00a0 30912 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary\u00a0S","family":"Buchwald","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-5662","authenticated-orcid":false,"given":"William\u00a0S","family":"Dynan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"},{"name":"Department of Biochemistry, Emory University School of Medicine , Atlanta , GA\u00a0 30322 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey\u00a0M","family":"Switchenko","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Rollins School of Public Health and Winship Cancer Institute, Emory University School of Medicine , Atlanta , GA\u00a0 30322 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7986-4335","authenticated-orcid":false,"given":"Baek","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine , Atlanta , GA\u00a0 30322 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad\u00a0K","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David\u00a0L","family":"Jaye","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine , Atlanta , GA\u00a0 30322 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2781-5379","authenticated-orcid":false,"given":"David\u00a0S","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Emory University School of Medicine , Atlanta , GA 30322,\u00a0 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"2024022421213153300_B1","author":"Padala","year":"2022"},{"key":"2024022421213153300_B2","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2024022421213153300_B3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"2024022421213153300_B4","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"2024022421213153300_B5","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1073\/pnas.1205299110","article-title":"Genetic heterogeneity of diffuse large B-cell lymphoma","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2024022421213153300_B6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"2024022421213153300_B7","first-page":"41","article-title":"Heterogeneity among diffuse large B-cell lymphoma: new entities in WHO classification, a first step in personalized therapy","volume":"60","author":"Rotaru","year":"2019","journal-title":"Rom. J. Morphol. Embryol."},{"key":"2024022421213153300_B8","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov."},{"key":"2024022421213153300_B9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/ng.373","article-title":"Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response","volume":"41","author":"Rice","year":"2009","journal-title":"Nat. Genet."},{"key":"2024022421213153300_B10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00109-021-02131-w","article-title":"SAMHD1 in cancer: curse or cure?","volume":"100","author":"Schott","year":"2022","journal-title":"J. Mol. Med. (Berl)"},{"key":"2024022421213153300_B11","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2013-04-490847","article-title":"SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage","volume":"123","author":"Clifford","year":"2014","journal-title":"Blood"},{"key":"2024022421213153300_B12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000500822","article-title":"Expression and relationship of SAMHD1 with other apoptotic and autophagic genes in acute myeloid leukemia patients","volume":"143","author":"Jiang","year":"2020","journal-title":"Acta Haematol."},{"key":"2024022421213153300_B13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-017-0036-5","article-title":"SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia","volume":"8","author":"Johansson","year":"2018","journal-title":"Blood Cancer J."},{"key":"2024022421213153300_B14","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/jid.2013.311","article-title":"Downregulation of SAMHD1 expression correlates with promoter DNA methylation in Sezary syndrome patients","volume":"134","author":"de\u00a0Silva","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"2024022421213153300_B15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jdcr.2015.05.003","article-title":"Aggressive CD8(+) epidermotropic cutaneous T-cell lymphoma associated with homozygous mutation in SAMHD1","volume":"1","author":"Merati","year":"2015","journal-title":"JAAD Case Rep"},{"key":"2024022421213153300_B16","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"key":"2024022421213153300_B17","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1073\/pnas.1519128113","article-title":"Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance","volume":"113","author":"Rentoft","year":"2016","journal-title":"Proc. Nat. Acad. Sci. U.S.A."},{"key":"2024022421213153300_B18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bbrc.2014.10.153","article-title":"SAMHD1 is down regulated in lung cancer by methylation and inhibits tumor cell proliferation","volume":"455","author":"Wang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2024022421213153300_B19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nature10623","article-title":"HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase","volume":"480","author":"Goldstone","year":"2011","journal-title":"Nature"},{"key":"2024022421213153300_B20","doi-asserted-by":"crossref","first-page":"43596","DOI":"10.1074\/jbc.C111.317628","article-title":"Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase","volume":"286","author":"Powell","year":"2011","journal-title":"J. Biol. Chem."},{"key":"2024022421213153300_B21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nm.4265","article-title":"Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies","volume":"23","author":"Herold","year":"2017","journal-title":"Nat. Med."},{"key":"2024022421213153300_B22","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41467-019-11413-4","article-title":"Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML","volume":"10","author":"Oellerich","year":"2019","journal-title":"Nat. Commun."},{"key":"2024022421213153300_B23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-018-0134-z","article-title":"Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens","volume":"8","author":"Rassidakis","year":"2018","journal-title":"Blood Cancer J."},{"key":"2024022421213153300_B24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nm.4255","article-title":"SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia","volume":"23","author":"Schneider","year":"2017","journal-title":"Nat. Med."},{"key":"2024022421213153300_B25","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.celrep.2017.08.008","article-title":"SAMHD1 promotes DNA end resection to facilitate DNA repair by homologous recombination","volume":"20","author":"Daddacha","year":"2017","journal-title":"Cell Rep."},{"key":"2024022421213153300_B26","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.3390\/cancers14184490","article-title":"Viral particle-mediated SAMHD1 depletion sensitizes refractory glioblastoma to DNA-damaging therapeutics by impairing homologous recombination","volume":"14","author":"Daddacha","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024022421213153300_B27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41586-018-0050-1","article-title":"SAMHD1 acts at stalled replication forks to prevent interferon induction","volume":"557","author":"Coquel","year":"2018","journal-title":"Nature"},{"key":"2024022421213153300_B28","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1038\/s41467-022-34578-x","article-title":"SAMHD1 deacetylation by SIRT1 promotes DNA end resection by facilitating DNA binding at double-strand breaks","volume":"13","author":"Kapoor-Vazirani","year":"2022","journal-title":"Nat. Commun."},{"key":"2024022421213153300_B29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.mrfmmm.2015.01.007","article-title":"Anthracyclines induce double-strand DNA breaks at active gene promoters","volume":"773","author":"Yang","year":"2015","journal-title":"Mutat. Res.\/Fundam. Mol. Mech. Mutagen."},{"key":"2024022421213153300_B30","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"2024022421213153300_B31","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"2024022421213153300_B32","doi-asserted-by":"crossref","first-page":"e2100265","DOI":"10.1200\/GO.21.00265","article-title":"Clinical outcomes of patients with B-cell non-hodgkin lymphoma in real-world settings: findings from the hemato-oncology latin america observational registry study","volume":"8","author":"Pavlovsky","year":"2022","journal-title":"JCO Glob. Oncol."},{"key":"2024022421213153300_B33","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"2024022421213153300_B34","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"2024022421213153300_B35","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"2024022421213153300_B36","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study","volume":"35","author":"van\u00a0Imhoff","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"2024022421213153300_B37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ccell.2019.07.007","article-title":"LMO2 confers synthetic lethality to PARP inhibition in DLBCL","volume":"36","author":"Parvin","year":"2019","journal-title":"Cancer Cell"},{"key":"2024022421213153300_B38","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-16-3068","article-title":"The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma","volume":"23","author":"Soumerai","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"2024022421213153300_B39","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors, P.","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"2024022421213153300_B40","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1038\/onc.2017.90","article-title":"Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype","volume":"36","author":"Guo","year":"2017","journal-title":"Oncogene"},{"key":"2024022421213153300_B41","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/embor.2010.153","article-title":"Cyclin-dependent kinase 9\u2013cyclin K functions in the replication stress response","volume":"11","author":"David","year":"2010","journal-title":"EMBO Rep."},{"key":"2024022421213153300_B42","doi-asserted-by":"crossref","first-page":"13546","DOI":"10.1073\/pnas.1301463110","article-title":"SIRT2 directs the replication stress response through CDK9 deacetylation","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2024022421213153300_B43","doi-asserted-by":"crossref","first-page":"21570","DOI":"10.1074\/jbc.C112.374843","article-title":"Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocyte-derived macrophages","volume":"287","author":"Kim","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2024022421213153300_B44","doi-asserted-by":"crossref","first-page":"e1002425","DOI":"10.1371\/journal.ppat.1002425","article-title":"SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection","volume":"7","author":"Berger","year":"2011","journal-title":"PLoS Pathog."},{"key":"2024022421213153300_B45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ni.2236","article-title":"SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates","volume":"13","author":"Lahouassa","year":"2012","journal-title":"Nat. Immunol."},{"key":"2024022421213153300_B46","doi-asserted-by":"crossref","first-page":"51545","DOI":"10.1074\/jbc.M408573200","article-title":"Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase","volume":"279","author":"Diamond","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2024022421213153300_B47","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2024022421213153300_B48","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"key":"2024022421213153300_B49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/path.2199","article-title":"The BCL6-associated transcriptional co-repressor, MTA3, is selectively expressed by germinal centre B cells and lymphomas of putative germinal centre derivation","volume":"213","author":"Jaye","year":"2007","journal-title":"J. Pathol."},{"key":"2024022421213153300_B50","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"2024022421213153300_B51","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"2024022421213153300_B52","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1074\/mcp.RA118.000652","article-title":"Doxorubicin-induced DNA damage causes extensive ubiquitination of ribosomal proteins associated with a decrease in protein translation","volume":"17","author":"Halim","year":"2018","journal-title":"Mol. Cell. Proteomics"},{"key":"2024022421213153300_B53","doi-asserted-by":"crossref","first-page":"e0275476","DOI":"10.1371\/journal.pone.0275476","article-title":"Doxorubicin induces prolonged DNA damage signal in cells overexpressing DEK isoform-2","volume":"17","author":"Ozcelik","year":"2022","journal-title":"PLoS One"},{"key":"2024022421213153300_B54","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nature10117","article-title":"SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx","volume":"474","author":"Laguette","year":"2011","journal-title":"Nature"},{"key":"2024022421213153300_B55","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.chom.2012.01.004","article-title":"The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx","volume":"11","author":"Lim","year":"2012","journal-title":"Cell Host Microbe"},{"key":"2024022421213153300_B56","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nm.4265","article-title":"Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies","volume":"23","author":"Herold","year":"2017","journal-title":"Nat. Med."},{"key":"2024022421213153300_B57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene therapy leaves a vicious cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front. Oncol."},{"key":"2024022421213153300_B58","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/v12101106","article-title":"Gene therapy applications of non-human lentiviral vectors","volume":"12","author":"Munis","year":"2020","journal-title":"Viruses"},{"key":"2024022421213153300_B59","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"2024022421213153300_B60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnol."}],"container-title":["NAR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/narcancer\/article-pdf\/6\/1\/zcae007\/56753955\/zcae007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/narcancer\/article-pdf\/6\/1\/zcae007\/56753955\/zcae007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T21:22:11Z","timestamp":1708809731000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/narcancer\/article\/doi\/10.1093\/narcan\/zcae007\/7613858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/narcan\/zcae007","relation":{},"ISSN":["2632-8674"],"issn-type":[{"value":"2632-8674","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2024,1,9]]},"article-number":"zcae007"}}